Lantheus (NASDAQ:LNTH) Coverage Initiated by Analysts at Redburn Atlantic

Redburn Atlantic began coverage on shares of Lantheus (NASDAQ:LNTH) in a research note released on Tuesday morning, MarketBeat reports. The brokerage issued a buy rating and a $175.00 price objective on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the company. Truist Financial dropped their price target on Lantheus from $141.00 to $135.00 and set a buy rating for the company in a research report on Thursday, August 1st. Leerink Partners lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an outperform rating in a research report on Thursday, July 11th. B. Riley upped their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a buy rating in a report on Thursday, July 25th. Finally, JMP Securities dropped their price objective on shares of Lantheus from $130.00 to $125.00 and set a market outperform rating for the company in a research note on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus currently has an average rating of Moderate Buy and an average target price of $126.00.

Lantheus Trading Down 3.2 %

Shares of LNTH stock opened at $101.98 on Tuesday. Lantheus has a 1-year low of $50.20 and a 1-year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The business’s fifty day moving average price is $102.61 and its 200 day moving average price is $81.26. The firm has a market capitalization of $7.07 billion, a PE ratio of 15.57 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The company had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.40 EPS. As a group, sell-side analysts forecast that Lantheus will post 6.03 EPS for the current fiscal year.

Insider Activity at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the completion of the transaction, the chief accounting officer now directly owns 62,557 shares in the company, valued at $4,990,171.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Gary J. Pruden sold 12,530 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total transaction of $1,190,851.20. Following the completion of the sale, the director now directly owns 11,978 shares of the company’s stock, valued at approximately $1,138,389.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Andrea Sabens sold 341 shares of the company’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $79.77, for a total value of $27,201.57. Following the sale, the chief accounting officer now owns 62,557 shares of the company’s stock, valued at $4,990,171.89. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,193 shares of company stock valued at $3,949,202. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new position in Lantheus in the second quarter valued at approximately $1,101,000. Clearbridge Investments LLC lifted its holdings in shares of Lantheus by 7.6% during the 2nd quarter. Clearbridge Investments LLC now owns 560,609 shares of the medical equipment provider’s stock valued at $45,011,000 after acquiring an additional 39,369 shares in the last quarter. Cetera Investment Advisers boosted its position in Lantheus by 34.8% during the 2nd quarter. Cetera Investment Advisers now owns 29,592 shares of the medical equipment provider’s stock worth $2,376,000 after purchasing an additional 7,640 shares during the period. Quarry LP increased its holdings in Lantheus by 51.3% in the 2nd quarter. Quarry LP now owns 1,145 shares of the medical equipment provider’s stock valued at $92,000 after purchasing an additional 388 shares in the last quarter. Finally, Creative Planning raised its position in Lantheus by 48.5% in the second quarter. Creative Planning now owns 23,714 shares of the medical equipment provider’s stock valued at $1,904,000 after purchasing an additional 7,742 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.